Welltower Valuation
Is WELL * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of WELL * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WELL * (MX$1583.95) is trading above our estimate of fair value (MX$1437.45)
Significantly Below Fair Value: WELL * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WELL *?
Other financial metrics that can be useful for relative valuation.
What is WELL *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$56.61b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 10.8x |
Enterprise Value/EBITDA | 28x |
PEG Ratio | 6.4x |
Price to Sales Ratio vs Peers
How does WELL *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 12.4x | ||
FIBRAPL 14 FIBRA Prologis | 16.4x | 11.8% | Mex$94.1b |
FUNO 11 Fibra UNO | 3.6x | 5.3% | Mex$95.0b |
EDUCA 18 Fideicomiso Irrevocable No. F/3277 en Banco Invex S. A. Institución de Banca Múltiple INVEX Grupo | 16.2x | 3.5% | Mex$66.3b |
FSITES 20 Fideicomiso Opsimex | 13.5x | n/a | Mex$88.1b |
WELL * Welltower | 8.5x | 9.6% | Mex$56.6b |
Price-To-Sales vs Peers: WELL * is good value based on its Price-To-Sales Ratio (8.5x) compared to the peer average (12x).
Price to Earnings Ratio vs Industry
How does WELL *'s PE Ratio compare vs other companies in the Global Health Care REITs Industry?
Price-To-Sales vs Industry: WELL * is expensive based on its Price-To-Sales Ratio (8.5x) compared to the Global Health Care REITs industry average (6.9x).
Price to Sales Ratio vs Fair Ratio
What is WELL *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 8.5x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate WELL *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.